A Placebo-controlled, Double-blind (Sponsor Open), Randomized, Crossover Study to Assess the Efficacy, Safety, and Tolerability of GSK2798745 in Participants With Chronic Cough
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 11 Apr 2018 Planned End Date changed from 4 Jan 2019 to 31 Jan 2019.
- 11 Apr 2018 Planned primary completion date changed from 4 Jan 2019 to 31 Jan 2019.
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.